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Abstract
Background: To comparatively evaluate the cardioprotective activity of placental growth factor (PGF) delivered
through direct injection and a nanoparticle-based system respectively and to study the underlying mechanisms in a
rat model of acute myocardial infarction (AMI).
Methods: Poly lactic-co-glycolic acid (PLGA)-based PGF-carrying nanoparticles (PGF-PLGANPs) were created. The mean
size and morphology of particles were analyzed with particle size analyzer and transmission electronic microscopy
(TEM). Encapsulation efficiency and sustained-release dose curve were analyzed by ELISA. Sprague-Dawley rats were
randomized into four groups (n = 10). While animals in the first group were left untreated as controls, those in the other
3 groups underwent surgical induction of AMI, followed by treatment with physiological saline, PGF, and PGF-PLGANPs,
respectively. Cardiac function was evaluated by transthoracic echocardiography at 4 weeks after treatment. At 6 weeks,
rats were sacrificed, infarction size was analyzed with Masson trichrome staining, and protein contents of TIMP-2,
MT1-MMP and MMP-2 at the infarction border were determined by immunohistochemistry and western blotting analysis.
Results: PGF was released for at least 15 days, showing successful preparation of PGF-PLGANPs. Coronary artery ligation
successfully induced AMI. Compared to physiological saline control, PGF, injected to the myocardium either as a nude
molecule or in a form of nanoparticles, significantly reduced infarction size, improved cardiac function, and elevated
myocardial expression of TIMP-2, MT1-MMP, and MMP-2 (P < 0.05). The effect of PGF-PLGANPs was more pronounced
than that of non-encapsulated PGF (P < 0.05).
Conclusion: Target PGF delivery to myocardium may improve cardiac function after AMI in rats. PLGA-based
nanoparticles appear to be a better approach to delivery PGF. PGF exerts its cardioprotective effect at least partially
through regulating metalloproteinase-mediated myocardial tissue remodeling.
Keywords: Placental growth factor, Acute myocardial infarction, Cardiac function, Nanoparticles-mediated drug
delivery, Vicious ventricular remodeling
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Background
Paracrine factors derived from stem cells have been de-
monstrated to be capable of improving cardiac function
after myocardial infarction (MI) and are now becoming a
hot topic of myocardial regeneration research [1,2].
One of these factors is placental growth factor (PGF).
A beneficial role for PGF in heart failure has been pre-
viously demonstrated in an animal study where auto-
implantation of myoblasts overexpressing PGF into
myocardium resulted in a significant functional im-
provement in the failing heart after ischemic MI [3].
However, the mechanisms underlying the benefits of
PGF in MI-associated heart failure have yet to be fur-
ther elucidated.
It has been documented that MI results in remodeling of
the myocardium, including the extracellular matrix (ECM)
[4]. Tissue inhibitors of metalloproteinases (TIMPs) are
critical regulators of ECM integrity, capable of inhibit-
ing the activity of ECM-degrading enzymes, matrix me-
talloproteinases (MMPs) [5]. Numerous types of MMPs
have been identified in mammals, of which membrane-
type-I MMP (MT1-MMP) is of a particular importance
in the regulation of ECM integrity. Through activating
MMP-2, MT1-MMP may aggravate the degradation and
loss of ECM [6]. However, it remains unclear whether
PGF may exerts its beneficial effect against ischemic
myocardial injury through regulating MMP-dependent
ECM degradation in the myocardium.
Various approaches to delivery exogenous agents in-
cluding PGF have been developed, of which, nanoparti-
cles have attracted considerable attention in recent years
worldwide [7]. Poly (lactic-co-glycolic acid) (PLGA), a
biodegradable polymer approved by U.S. Food and Drug
Administration for drug delivery, is one of the widely
used types of carriers [8]. Due to its properties of surface
erosion and subsequent constant matrix erosion, PLGA
allows for slow drug release [9]. Besides sustained re-
lease, PLGA-based nanoparticles as drug carriers possess
advantages of increased freedom and better permeability
into interstitial spaces. Nevertheless, delivery of PGF-
carrying PLGA nanoparticles (PGF-PLGANPs) into myo-
cardium has been seldom reported.
This study aimed to investigate the therapeutic efficacy
of PGF-PLGANPs-bearing nanoparticles against acute
myocardial infarction (AMI) in comparison with direct
administration of PGF as well as the mechanistic role of
TIMP-2, MT1-MMP and MMP-2-regulated cardiac re-
modeling in PGF-mediated cardioprotection in a rat
model.
Methods
All human studies have been approved by shanghai Ren Ji
Hospital Ethics Committee and performed in accordance
with the ethical standards
Preparation of PGF-PLGANPs
PLGA (100 mg; block ratio: 50:50; viscosity: 0.53 dl/g;
average molecular weight: 6.0 × 104), purchased from
Shandong Institute of Medical Devices (Shandong, China),
was dissolved in 0.5 ml ethyl acetate as an oil phase (O).
Recombinant human PGF, purchased from R&D Systems
(catalog #264-PG-050, Minneapolis, MN, USA), was dis-
solved in H2O (0.50 μg/μl) as a water phase (W1). W1
was then dripped slowly into O to create the W1/O emul-
sion through ultrasonication. W1/O was added into 2 ml
19% pluronic F-68 solution to form W1/O/W2 double
emulsions. Ethyl acetate was evaporated under a vacuum
and the PLGA nanoparticles were collected after high
speed centrifugation (6000 rpm, 8 min). Finally, PGF-
PLGANPs were lyophilized. The dose of PGF was chosen
based on a previous study [10].
Assessment of in vitro release kinetics and
encapsulation efficiency
To analyze in vitro release kinetics, PGF-PLGANPs (con-
taining 30 μg PGF) were suspended in 16 ml of
phosphate-buffered saline (PBS, PH 7.4). The suspension
solution was then placed in an environment of 37°C with
horizontal shaking for 15 days. During this period, 1 ml of
the medium was sampled twice (12 h and 24 h) on the
first day and once every two days thereafter. The concen-
tration of PGF released at different time points was deter-
mined by enzyme-linked immunosorbent assay (ELISA)
as previously described [11]. All experiments were con-
ducted in triplicate. The amount of encapsulated PGF was
determined as the difference between the initial amount
and residual amount in the supernatant. The average size
and morphology of the nanoparticles were assessed under
the NICOMP380 ZLS (Particle sizing systems, USA) and
H-600 transmission electron microscopy (HITACHI,
Japan). The percent encapsulation efficiency was calcu-
lated as: ¼ Mass of total drug‐Mass of free drugð ÞMass of total drug  100% , and the
drug loading as: ¼ Mass of total drug‐Mass of free drugð ÞMass of microspheres  100%:
Animals, AMI induction and treatment
Sprague-Dawley rats (250 ± 50 g, 8-10 weeks) were ob-
tained from the Experimental Animal Center, Shanghai
Jiaotong University-Affiliated Renji Hospital, China.
They were housed in groups (4 per cage) with free access
to a regular diet and clean drinking water. All the experi-
mental procedures described below adhered strictly to the
guidelines set forth by the National Science and Technol-
ogy Commission of China and approved by the institu-
tional ethics committee.
For AMI induction, rats were anesthetized with an intra-
peritoneal dose of 0.2 ml 2% pentobarbital under intubated
mechanical ventilation at 80 breaths per minute. Thoraco-
tomy was performed through the fourth intercostal space,
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and the left anterior descending coronary artery was identi-
fied and ligated with 6.0 prolene suture in the middle por-
tion. A few minutes after ligation, pallor and akinesia were
seen in the anterior wall and apical left ventricular area.
The interface between the pale and normal areas was de-
fined as ‘infarction border zone’. The presence of infarction
zone and ST segment elevation were considered as criteria
of successful induction of AMI. A group of animals (n = 10)
were left untreated controls. The animals that were success-
fully induced to develop AMI were randomized to receive
30 μl PBS (n = 10), non-encapsulated PGF (2 μg in 30 μl so-
lution, n = 10), and PGF-PLGANPs (2 μg in 30 μl solution,
n = 10), respectively. The injection of 30 μl was adminis-
trated around the pale areas: upper, center, and lower with
10 μl in each area. All agents were delivered to the infarc-
tion border zone through intramyocardial injection using a
micro-syringe.
Cardiac function determination
Echocardiographic examinations were performed 4 weeks
after surgery under inhaled isoflurane (0.2%) anesthesia,
with the Vevo770 ultrasound system (Visualsonics
Inc., Toronto, Canada). The frequency of the probe
was set at 17.5 MHz, sampling frequency in M-mode
at 1000/s, and scanning speed 50-100 mm/s. The
probes were placed on precordium and the detection
was carried out from the section of ventricular bands.
Left ventricular anterior wall (LVAW) thickness, left
ventricular end-diastolic diameters (LVEDD), and left
ventricular end-systolic diameters (LVESD) were mea-
sured. Based on these measurements, left ventricular
end-diastolic volume (LVEDV), left ventricular end-
systolic volume (LVESV), left ventricular ejection frac-
tion (LVEF) and left ventricular fraction shortening
(LVFS) were calculated as follows:
LVEDV ¼ 7:0 LVEDD
3
2:4þ LVEDDð Þ;
LVESV ¼ 7:0 LVESD
3
2:4þ LVESDð Þ;
LVEF ¼ LVEDV‐LVESVð Þ
LVEDV
 100%;




Six weeks after AMI surgery, rats were anesthetized by in-
haled isoflurane (0.2%) followed by cardiac perfusion with
100 ml 4% triformol. Animals were then sacrificed by
rapid excision of heart. Hearts were excised and soaked
immediately in saline to remove the excess blood from the
ventricles before being fixed in 4% triformol. Paraffin-
embedded samples were sectioned at 5 μm and
Masson’s trichrome staining was performed. Digital
images of the stained sections were captured and tissue
scar was analyzed with Image Pro-Plus 6.0 software.
The size of infarct was also calculated as previously
described [12].
Imunohistochemical analysis
This was performed using the DAKO EnVision™ + System
(Glostrup, Denmark). Briefly, paraffin-embedded sections
(5 μm) were dewaxed, and incubated with the primary
antibody TIMP-2 (Abcam, Cambridge, MA, USA, cata-
log #ab1828), MT1-MMP (Abcam, catalog #ab51074),
MMP-2 (Abcam, catalog # ab80737) and Envision. After
the visualization with diaminobenzidine (DAB), images
were acquired under the Axioplan 2 automatic fluores-
cence microscopy (Carl Zeiss) and the intensity of the
corresponding protein bands were analyzed using the
Axioplan 2 imaging software.
Western blotting analysis
Infarcted tissue specimens collected from the border
zone were homogenized in 1% Triton X-100, 10 mM
Tris-HCl (PH 7.6). After centrifugation at xxxx g for xx
min, the supernatant was collected. Concentration of
total proteins in the supernatant was quantitated. Ten
μg proteins from each sample prepared in a buffer con-
taining 2% sodium dodecyl sulfate (SDS) were separated
by electrophoresis on a SDS-PAGE and then transferred
to a nitrocellulose membrane blot. After blocking in 5%
skimmed milk in TBST (0.1% Tween 20) for 1 hour, the
blot was incubated with primary antibodies respectively
against TIMP-2 (Abcam, ab1828), MT1-MMP (Abcam,
ab51074), MMP-2 (Abcam, ab80737) at 4°C overnight.
Following washing, the blot was incubated with a HRP
anti-rabbit secondary antibody (Santa Crutz, CA, USA) for
1 hour at room temperature. After another three rounds
(10 min/time) of washing in TBST, the blot was developed
by enhanced chemiluminescence (ECL) as instructed by the
manufacturer. For the purpose of loading control, the blot
was stripped and re-probed with GAPDH. The immuno-
reactive bands of the interest protein and GAPDH protein
were densitometricaly analyzed with Image J software (Na-
tional Institutes of Health, USA).
Statistical analysis
Data were expressed as mean ± standard deviation. In-
tergroup comparison was analyzed by t test, and the
intra comparison was conducted by paired t test. All
statistical analyses were performed using SPSS 10.7 soft-
ware (Chicago, IL, USA). Differences were considered
significant when P < 0.05.




PGF-PGF-PLGANPs had a regular spherical shape with
good integrity, even distribution, and smooth surface, as
demonstrated by electron microscopy (Figure 1A). The
average diameter of the nanoparticles was 233.9 ± 15.3 nm
and the average encapsulation efficiency was 43.52 ±
4.21% (Figure 1B).
In vitro release kinetics of PGF-PLGANPs
Shown in Figure 2 are concentrations of PGF released
from PGF-PLGANPs at different time points during the
15-day experiment as determined by ELISA. In the first
1-5 days, PGF release was rapid, amounting for more
than 60% of the total release. After that, the daily release
amount became more stable. By day 14 or 15, 80% of
PGF was released.
Echocardiography findings
Echocardiography was performed on all animals at
4 weeks after surgery. Compared to animals in the
sham group (Figure 3A), those in the other three groups
showed different degrees of enhanced myocardial echo,
thinning of the left ventricular wall and weakened contrac-
tions (Figure 3B-D). The LVEF, LVFS, and LVAW in PGF-
PLGANPs group were all significantly higher than those in
the PGF and AMI control groups (P < 0.05, Table 1).
Myocardial scar
Shown in Figure 4 are Masson trichrome staining results.
There were significant differences (P < 0.05) in the average
scar area between groups (Figure 4A). In the cardiac
tissue sections, viable myocardium was stained red,
while fibrosis due to infarction damage was stained
blue. In the sham operation control group, no area was
stained blue (Figure 4B1). In contrast, the infarcted
zone in the non-treatment AMI control group was
filled with blue scar tissues (Figure 4B2). Treatment
with both non-encapsulated PGF (Figure 4B3) and
PGF-PLGANPs (Figure 4B4) reduced the area stained
blue and the intensity of blue staining. However, the ef-
fect of PGF-PLGANPs was more pronounced; myocar-
dial compensatory hypertrophy was seen in the PGF
group.
Protein contents of TIMP-2, MT1-MMP, and MMP-2
Shown in Figure 5 are the results of immunohistochemical
staining assessment of TIMP-2, MT1-MMP, and MMP-2
protein signals in the cardiac specimens (Figure 5).
The immunoreactive signal for TIMP-2 was strong
in the sham operation group but became significantly
weakened after AMI surgery (P < 0.05). Both non-
encapsulated PGF and PGF-PLGANPs significantly
attenuated AMI-associated decrease in the reactive
signal for TIMP-2 (P < 0.05). In contrast, immunoreac-
tive signals for MT1-MMP and MMP-2 all showed a
pattern of changes in different groups totally opposite
to the pattern for TIMP-2.
Changes in TIMP-2, MT1-MMP, and MMP-2 protein
contents in different groups were also analyzed by
Western blotting. Similar patterns to those for these
proteins shown in immunohistochemical staining were
observed (Figure 6).
Figure 1 Characterization of nanoparticles. A: morphology revealed by transmission microscopy. B: bar graphs, showing the average
diameters detected by NICOMP 380 ZLS.
Figure 2 In vitro cumulative release curve of PGF-PLGANPs
nanoparticles.
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Discussion
MI is a life-threatening clinical condition. Even though
the symptoms of myocardial ischemia can be partly im-
proved by pharmacologic agents, delivered either surgi-
cally or non-surgically, yet the malignant myocardial
remodeling caused by MI cannot be reversed. PGF, one
of the cytokines belonging to VEGF family, binds to flt-1
receptors in its target cells including cardiac myocytes,
cardiac fibroblasts, and bone marrow derived cells [13]
and then activates downstream signals important in
myocardial damage repair [14,15], angiogenesis [16], in-
flammatory response [17], and peripheral stem cell dis-
tribution [18]. Given that PGF intervention after AMI
results in an increase in specific gene transcripts, PGF is
regarded as a prognostic marker of acute coronary syn-
drome [19]. To evaluate the cardioprotective potential of
PGF, we determined the effect of PGF, injected into the
infarction zone of the myocardium either as a nude molecule
or in a form of nanoparticles, on the cardiac function after
AMI in a rat model in this study. First, we found that both
PGF and PGF-PLGANPs significantly increased LVEF, re-
duced scar tissue formation, thus leading to recovery of
cardiac function, in animals after AMI induction. How-
ever, the improvement in all these variables was more sig-
nificant for PGF-PLGANPs than PGF.
In order to investigate the mechanism underlying the
cardioprotective activity of PGF, we analyzed changes in
protein contents of MMPs (MT1-MMP, MMP-2) and its
inhibitor (TIMP-2) in infarcted area. The protein con-
tent of TIMP-2 at the baseline level was high, but it was
reduced after-AMI. PGF intervention was effective to at-
tenuate the reduction. In contrast, an opposite pattern
of changes was observed for MT1-MMP and MMP-2
proteins. MMPs belong to a family of Zn2+-dependent
enzymes known to cleave ECM proteins under normal
and pathological conditions [20,21]. TIMP-2 may promote
Figure 3 Echocardiography of rats in the control group (A), AMI group (B), PGF group (C) and PGF-PLGANPs group (D) at the end of the
fourth week after AMI surgery.
Table 1 Cardiac function parameters assessed by echocardiography
Parameters
Groups LVEF (%) LVFS (%) LVAW (mm) Heart rate
Sham 81.28 ± 3.70 51.78 ± 11.26 3.23 ± 0.60 478 ± 47
AMI 21.03 ± 6.36# 8.74 ± 4.08# 0.87 ± 0.14# 497 ± 52
PGF 27.71 ± 4.59#& 16.29 ± 6.91#& 1.28 ± 0.28#& 462 ± 61
PGF-PLGANPs 40.61 ± 8.11
#&※ 26.63 ± 9.27#&※ 1.35 ± 0.38#& 481 ± 59
AMI acute myocardial infarction; LVEF left ventricular ejection fraction; LVFS left ventricular fraction shortening; LVAW Left ventricular anterior wall. #p < 0.05,
compared with sham group; & p < 0.05, compared with AMI group; ※p < 0.05, compared with PGF group.
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the conversion from pro-MMP-2 to mature MMP-2, act-
ing as a key protein regulating ECM degradation after
AMI [22]. Under exogenous PGF intervention, a compen-
satory increase in TIMP-2 and MT1-MMP expression oc-
curs, leading to an increased production and/or activation
of pro-MMP-2 through MT1-MMP [23]. In the process of
ECM degradation, MT1-MMP and MMP-2 exert syner-
gistic effects; type I collagen is initially degraded by MT1-
MMP and the product subsequently degraded by MMP-2
[23,24]. Our observations in this study are consistent with
the established cascade of ECM degradation in the infarcted
myocardial zone after AMI. We also observed myocardial
necrosis and collagen, followed by gradual scarring. A large
area of blue scar tissues was detected in AMI group,
followed by a decrease in TIMP-2 protein content in the
myocardium. Following PGF intervention, both TIMP-2
and MMP-2 increased in protein content, resulting in ac-
celerated collagen degradation, in the scar tissue in the MI
zone, facilitating the implantation of the new-born car-
diomyocytes. TIMP-2 is a natural inhibitor of both
MT1-MMP and MMP-2. TIMP-2 deficiency completely
abrogates MMP-2 activation but markedly increases activ-
ities of various collagenases, particularly MT1-MMP, after
MI [5]. Based on our immunohistochemical and Western
blotting analysis results, we suggest that post-AMI inter-
vention with PGF may promote the expression recovery
of TIMP-2, thus activating MMPs, inhibiting the forma-
tion of scar tissues and improving ventricular remodeling.
Nanoparticles are submicron-sized polymeric particles
encapsulated with a therapeutic agent within the poly-
meric matrix or conjugated or absorbed onto their surface
[25], allowing for a controlled release of active agents to
the specific site of action at a therapeutically optimal rate
[26]. PGF has a short half-life and is not suitable to be
exposed in tissues. To obtain a sustained slow-release,
multiple types of the nanoparticles have been used to
deliver PGF in human body. For instance, in the study
of Mohammed et al, they used chitosan-alginate nanopar-
ticle [10], while in this study PLGA was used. We showed
that nanoparticles-based delivery enabled persistent and
sustained release of PGF, supporting the superiority of
nano-materials in drug delivery [27], due to their excellent
biocompatibility and biodegradability [28]. It was consist-
ent with the study of Mohammed et al. and others [29,30].
The main advantage of using PLGA as a carrier is that the
release profile can be modified by different parameters,
such as molecular weight and lactide to glycolide ratio. In
this study, a consistently slow release of PGF from nano-
particles was demonstrated during the 15-day period of
test. Another advantage of PLGA-based drug delivery is a
burst release in the initial period. In this study, an initial
burst release of PGF (10% of total approximately) was
observed on the first day. Given significant increases in
the expression of pro-inflammatory cytokines and MMPs
the first 3 days after AMI [31], the burst release of PGF
observed in this study may have important clinical
implications.
Conclusion
PGF may improve the cardiac function after AMI, possibly
through a mechanism involving TIMP-2, MT1-MMP, and
MMP-2-associated ECM degradation ad tissue remodeling
Figure 4 Effect of PGF on myocardial scar formation after AMI. A: A bar graph showing the average scar area in different groups. Symbols
indicate significant differences (P < 0.05) from the control group (#), from the non-treatment AMI group (&), and from the nude PGF group (※),
respectively. B: Digital images (×7.5) of tissue sections stained by Masson Trichrome in the control group (B1), AMI group (B2), PGF group (B3)
and PGF-PLGANPs group (B4). Red color indicates viable myocardium, while blue color indicates fibrosis due to infarction damage.
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Figure 5 Immunohistochemical signals of TIMP-2 (A1-D1), MT1-MMP (A2-D2), and MMP-2 (A3-D3) (×200) in myocardium in the control
group (A), non-treatment AMI group (B), PGF group (C), and PGF-PLGANPs group (D). The densitometric data on the corresponding
signals in A, B, C and D are presented as bar graphs in E. Symbols indicate significant differences (P < 0.05) from the control group (#), from
the non-treatment AMI group (&), and from the nude PGF group (※), respectively.
Figure 6 Content changes of TIMP-2, MT1-MMP, and MMP-2 detected by western blotting. A: Representative Western blots, showing
bands of TIM-2, MT1-MMP and MMP-2 in myocardial specimens collected from the indicated groups. B: Bar graphs, showing the densitometric
data corresponding to A. Symbols indicate significant differences (P < 0.05) from the control group (#), from the non-treatment AMI group
(&), and from the nude PGF group (※), respectively.
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in the myocardium. Due to well-controlled release proper-
ties, PGF-PLGANPs system developed in this study offers a
superior approach of myocardial delivery of PGF. Further
studies are warranted on the mechanisms underlying the
cardioprotective activity of PGF in AMI as well as on the
optimized dose and administration time window of PGF-
PLGANPs as a potential therapeutic approach for AMI.
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